A. John Ashcroft

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · The Lancet · 2010 · 566 citations · Full text

Hematological Malignancy, Zoledronic Acid, Oncology +8

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

Faith E. Davies, Ann Dring, Cheng Li et al. · Blood · 2003 · 226 citations

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

Andy C. Rawstron, Faith E. Davies, Ranjit Dasgupta et al. · Blood · 2002 · 209 citations

Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin

A. John Ashcroft, Sheena Cruickshank, Peter I. Croucher et al. · Immunity · 2003 · 180 citations · Full text

Inflammation, Sclerostin, Autoimmune Disease +11

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

Gareth J. Morgan, J. Anthony Child, Walter M. Gregory et al. · The Lancet Oncology · 2011 · 161 citations · Full text